Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03726515 · ClinicalTrials.gov registry record · Phase 1
CART-EGFRvIII + Pembrolizumab in GBM
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03726515: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT03726515 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03726515, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL CART-EGFRvIII T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2021-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03726515
The ClinicalTrials.gov registry entry for NCT03726515 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03726515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03726515 about?
NCT03726515 is a clinical study titled "CART-EGFRvIII + Pembrolizumab in GBM". This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
What is the current status of trial NCT03726515?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-03-11. Estimated completion is 2021-02-27.
What interventions are being tested in trial NCT03726515?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), CART-EGFRvIII T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03726515?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.